High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group (vol 8, 115, 2015)

Journal of Hematology & Oncology

BIOMED CENTRAL LTD

1. NCI NIH HHS [U10 CA180899] Funding Source: Medline